Shi Yuankai

[Expert Profile] Shi Yuankai, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in medical oncology in China, working at the Cancer Hospital of the Chinese Academy of Medical Sciences. He has long been dedicated to clinical diagnosis, treatment, and new drug development for relapsed/refractory solid tumors and difficult medical oncology cases, and is an important leading figure in medical oncology in China.

[Education & Career] Professor Shi Yuankai graduated from a renowned medical university, completed systematic medical oncology training at the Cancer Hospital of the Chinese Academy of Medical Sciences, and further studied at famous international cancer centers. He has long served as Vice President of the Cancer Hospital of the Chinese Academy of Medical Sciences, holding important academic positions including Chair of the Clinical Chemotherapy Professional Committee of the Chinese Anti-Cancer Association. He has presided over grants from major national new drug development projects, and is a representative scholar in the fields of medical oncology and anti-tumor new drug development in China.

[Areas of Expertise] Professor Shi specializes in comprehensive treatment of relapsed/refractory solid tumors, medical treatment of difficult tumors, and standardized chemotherapy, targeted therapy, and immunotherapy for common tumors such as lung cancer and lymphoma. He has extensive experience in early clinical research and standardized application of novel anti-tumor drugs (targeted drugs, immune checkpoint inhibitors, ADC drugs, etc.). He excels at identifying and recommending the most appropriate innovative treatment options for "refractory tumor patients who fail standard therapy," helping numerous patients gain new treatment opportunities.

[Academic Achievements & Industry Contributions] Professor Shi has led a large number of clinical studies on domestic anti-tumor new drugs, presided over and completed registration clinical trials for multiple China-developed targeted and immunotherapy drugs, driving China's anti-tumor drug development from imitation to innovation, with findings published in top international oncology journals. He has led the development of Chinese medical oncology-related diagnosis and treatment standards, actively promoted the standardized application of novel anti-tumor drugs and the construction of multi-center clinical research systems, and made outstanding contributions to the development of medical oncology and new drug innovation in China.

[Clinical Practice & Outstanding Contributions] Professor Shi has long held expert medical oncology clinics, cumulatively treating tens of thousands of patients with various tumors, securing innovative treatment opportunities for numerous relapsed/refractory patients. Leading his team, he has established a comprehensive medical oncology whole-course management system and clinical research platform, and has repeatedly organized national multi-center clinical studies. He has received multiple national and industry honors, and is deeply trusted by patients and respected by peers alike. He is an authoritative expert in the field of medical oncology in China.

[Honors & Reputation] Professor Shi Yuankai serves as Vice President of the Cancer Hospital of the Chinese Academy of Medical Sciences and Deputy Director of the National Cancer Center, among other academic positions. He has presided over national-level projects including the National Key R&D Program, and is an authoritative expert in the field of medical oncology in China. He has profound expertise in standardized diagnosis, treatment, and new drug development for relapsed/refractory solid tumors and difficult medical oncology cases. He has led multiple clinical trials of anti-tumor new drugs, promoted independent research and standardized application of anti-tumor drugs in China, participated in the development of multiple tumor diagnosis and treatment guidelines and expert consensus statements, and has research findings published in international authoritative journals, receiving multiple science and technology awards. For decades on the clinical front lines, he has helped numerous difficult tumor patients receive standardized treatment, and is deeply trusted by patients and respected by peers alike.